CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex assay (HIV 1/2, HBV and HCV), performed on the Tigris testing platform, to the -enhanced Ultrio Elite triplex assay performed on the Panther testing platform on July 13, 2020. The implementation date has been moved up to July 7th. Contact your Customer Service Manager if you have any questions!
CTS will be revising some forms in use by clients on October 26, 2020. We do try to limit form chang...
We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...
Reminder - The CTS Reentry form, CTS-00172, will be updated on Monday July 2, 2018. It's posted ...
CTS was recently notified that one of the tubes listed in the Sample Acceptability document...
After a recent reevaluation of the Monolisa anti-HBs EIA package insert, the CTS QA/Scientific team ...